(firstQuint)A Study to Evaluate the Safety and Efficacy Imiquimod Cream, 2.

5% in Subjects With Actinic Keratoses.

 Aldara(R) (imiquimod) Cream, 5% was the first imiquimod product approved by the FDA for the topical treatment of actinic keratosis, superficial basal cell carcinoma and external genital and perianal warts.

 The FDA approved regimen for the treatment of AK is application of 250 mg of cream twice a week for 16 weeks to a 25-cm2 area.

 In 2011, a lower strength imiquimod cream, Zyclara (imiquimod) Cream, 2.

5% was approved by the FDA.

 When used for the treatment of AK, Zyclara is applied for a shorter duration and in an expanded treatment area (e.

g.

, face or scalp) in comparison to Aldara(R).

 This study will be conducted in compliance with the protocol, Good Clinical Practice (GCP) and the applicable regulatory requirement(s).

 Marketed by Medicis, Zyclara(R) (imiquimod) cream 2.

5% is a safe and effective topical therapy for the treatment of actinic keratosis of the face and scalp.

 Actavis has developed a generic formulation of imiquimod 2.

5% cream and the current study is designed to evaluate the safety and efficacy of this formulation.

.

 A Study to Evaluate the Safety and Efficacy Imiquimod Cream, 2.

5% in Subjects With Actinic Keratoses@highlight

The purpose of this study it so compare the safety and efficacy profiles of a generic imiquimod 2.

5% cream to the reference listed Zyclara(R) (imiquimod) cream in the treatment of actinic keratosis.

